Concisely, the current trial sequential meta-analysis of the published case–control reports will help in strengthening the postulated pharmcogenetic association of NAT2 genetic variants with INH-induced hepatotoxicity risk in TB patients. The gene discussed is NAT2; the disease is tuberculosis.